In this study, we show that AFF3 is overexpressed in ER+ human breast cancers, leading to tamoxifen resistance and estrogen-independent growth, and that patients with primary breast cancers with AFF3 overexpression have worse survival. Here, AFF3 is linked to breast carcinoma.